Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands¹. Among these, primary open-angle glaucoma is the predominant subtype, impacting approximately 100,000 people².

Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ by Prof. Henny Beckers, Head of the Glaucoma Clinic and Director of the Ophthalmology Residency Program.

iSTAR Medical’s rollout of MINIject^® in the Netherlands adds to its existing portfolio of European countries. MINIject^® continues to demonstrate meaningful and sustained performance in lowering intraocular pressure (IOP) combined with a favorable safety profile.

Prof. Henny Beckers, Head of the Glaucoma Clinic and Director of the Ophthalmology Residency Program at the University Eye Clinic of the Maastricht University Medical Center+ in the Netherlands commented: “I am happy to report the successful initiation of the first MINIject^®procedures at our clinic and pleased to have already received positive feedback from the patients following the procedure. We are confident that the addition of this new suprachoroidal procedure into our treatment portfolio holds the potential to benefit a significant number of patients in the future.”

Michel Vanbrabant, CEO of iSTAR Medical, commented: “iSTAR Medical continues to make significant progress in the global commercial rollout of MINIject^® and I am proud with this achievement in the Netherlands to close 2023. We would like to extend our thanks to the team at the University Eye Clinic of the Maastricht University Medical Center+ for completing the first surgeries and for their contribution towards achieving our aim of improving the lives of people around the world affected by glaucoma.”